Nonpeptidergic allosteric antagonists differentially bind to the CXCR2 chemokine receptor

P. de Kruijf, J.T. van Heteren, H.D. Lim, P. Conti, M.M. van der Lee, L. Bosch, K.K. Ho, D.S. Auld, M. Ohlmeyer, M.J. Smit, J.C. Wijkmans, G.J. Zaman, R. Leurs

Research output: Contribution to JournalArticleAcademicpeer-review

Abstract

The chemokine receptor CXCR2 is involved in different inflammatory diseases, like chronic obstructive pulmonary disease, psoriasis, rheumatoid arthritis, and ulcerative colitis; therefore, it is considered an attractive drug target. Different classes of small CXCR2 antagonists have been developed. In this study, we selected seven CXCR2 antagonists from the diarylurea, imida-zolylpyrimide, and thiazolopyrimidine class and studied their mechanisms of action at human CXCR2. All compounds are able to displace
Original languageEnglish
Pages (from-to)783-90
JournalThe Journal of Pharmacology and Experimental Therapeutics
Volume329
Issue number2
DOIs
Publication statusPublished - 2009

Fingerprint Dive into the research topics of 'Nonpeptidergic allosteric antagonists differentially bind to the CXCR2 chemokine receptor'. Together they form a unique fingerprint.

Cite this